Activation of pain by sumatriptan.

Autor: Coulter DM; Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand., Passier JL, Clark DW, van Puijenbroek EP
Jazyk: angličtina
Zdroj: Headache [Headache] 2003 Oct; Vol. 43 (9), pp. 994-9.
DOI: 10.1046/j.1526-4610.2003.03192.x
Abstrakt: Objective: To demonstrate that sumatriptan may induce activation or aggravation of pain at sites of inflammation caused by trauma or disease.
Methods: Case reports from the national pharmaco vigilancecenters of 2 countries, The Netherlands and New Zealand, are presented. These reports come from programs that use 2 methodologies to monitor drugs for adverse reactions: spontaneous reporting and a prospective observational cohort study. The potential mechanisms for pain production by sumatriptan are discussed in detail.
Results: Thirteen case reports of activation of pain by sumatriptan following injury and 8 associated with inflammatory diseases are presented. Most patients had one or more positive rechallenges. This type of reaction occurred at a higher rate with the subcutaneous formulation than with the oral preparation. Pain mostly was severe but short-lasting; pain was prolonged in some patients with inflammatory disease.
Conclusions: A strong association has been demonstrated between the use of sumatriptan and the production of pain at sites of inflammation, and there is a plausible pharmacological mechanism for this reaction. Pain activation may be a class effect of the selective serotonergic agonists used in the treatment of migraine.
Databáze: MEDLINE
Externí odkaz: